HIV-1 inhibitor 5b

Research use only, not for human use.

HIV-1 inhibitor 5b is a novel anti-HIV-1 compound that inhibits HIV-1 JR-CSF with EC50 of 1 nM without significant cytotoxicity (CC50>20 uM).

HIV-1 inhibitor 5b is a novel anti-HIV-1 compound that inhibits HIV-1 JR-CSF with EC50 of 1 nM without significant cytotoxicity (CC50>20 uM), also shows potency against NRTI- and NNRTI-resistant HIV-1 (EC50=1-3 nM); shows a chemical backbone similar to the clinically used integrase (IN) strand transfer inhibitor (INSTI) elvitegravir, but has no detectable INSTI activity; various drug-resistant HIV-1 strains did not display cross resistance to HIV-1 inhibitor 5b; remains its anti-HIV-1 activity even after the viral integration stage, significantly suppresses p24 antigen production in HIV-1 latently infected cells exposed with TNF-alpha; demonstrates favorable pharmacokinetic profiles in mice.

——

Microbiology/Virology

HIV

HIV

——

——

--

369.37

C20H17F2N3O2

>98% (HPLC)

——

——

1-(5-amino-2,4-difluorophenyl)-7-(3,5-dimethyl-4,5-dihydroisoxazol-4-yl)quinolin-4(1H)-one

(-20℃)

With Ice Pack

≥ 2 years